MedTrace Logo

Adult Dengue Platelet Study

NCT01030211 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2015-08-25

No results posted yet for this study

Summary

Retrospective data in children with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), and in adults with dengue fever (DF), suggested a lack of benefit from prophylactic platelet transfusion for severe thrombocytopenia in dengue patients without bleeding. However, in Taiwan and Singapore, platelet transfusion was given to 13-50% of hospitalised dengue patients. This is a prospective randomised study to examine the safety and efficacy of prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without bleeding.

The hypotheses are:

1. Prophylactic platelet transfusion is safe in hospitalised dengue patients with severe thrombocytopenia.
2. Prophylactic platelet transfusion is effective in preventing bleeding in hospitalised dengue patients with severe thrombocytopenia.

Conditions

  • Dengue Fever

Interventions

PROCEDURE

Platelet transfusion

4 units of platelets for patients with platelet count \<20x10\^3/uL

OTHER

Supportive care

Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • Changi General Hospital

    collaborator OTHER

  • National University Hospital, Singapore

    collaborator OTHER

  • University of Malaya

    collaborator OTHER

  • Tan Tock Seng Hospital

    lead OTHER

Principal Investigators

  • Yee S Leo, FRCP · Tan Tock Seng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Malaysia
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030211 on ClinicalTrials.gov